[(4-Chloro-benzyl)-(4-methoxy-benzenesulfonyl)-amino]-acetic acid ethyl ester | 188292-70-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(4-Chloro-benzyl)-(4-methoxy-benzenesulfonyl)-amino]-acetic acid ethyl ester
• 英文别名: Ethyl 2-[(4-chlorophenyl)methyl-(4-methoxyphenyl)sulfonylamino]acetate
• CAS: 188292-70-8
• 化学式: C₁₈H₂₀ClNO₅S
• 分子量: 397.88
• InChiKey: XZHNUFIVLVMAGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  81.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  [(4-Chloro-benzyl)-(4-methoxy-benzenesulfonyl)-amino]-acetic acid ethyl ester 在 盐酸羟胺 、 sodium methylate 作用下， 以 甲醇 为溶剂， 生成 N-Hydroxy-2-[[4-methoxybenzenesulfonyl](4-chlorobenzyl)amino]acetamide
  参考文献：
  名称：

  Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits

  摘要：

  Structure-activity relationships of a lead hydroxamic acid inhibitor of recombinant human stromelysin were systematically defined by taking advantage of a concise synthesis that allowed diverse functionality to be explored at each position in a template. An ex vivo rat model and an in vivo rabbit model of stromelysin-induced cartilage degradation were used to further optimize these analogs for oral activity and duration of action. The culmination of these modifications resulted in CGS 27023A, a potent, orally active stromelysin inhibitor that blocks the erosion of cartilage matrix.

  DOI：

  10.1021/jm960871c
• 作为产物：
  描述：

  对甲氧基苯磺酰氯 在 sodium hydride 、 三乙胺 作用下， 以 氯仿 为溶剂， 反应 2.5h， 生成 [(4-Chloro-benzyl)-(4-methoxy-benzenesulfonyl)-amino]-acetic acid ethyl ester
  参考文献：
  名称：

  Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits

  摘要：

  Structure-activity relationships of a lead hydroxamic acid inhibitor of recombinant human stromelysin were systematically defined by taking advantage of a concise synthesis that allowed diverse functionality to be explored at each position in a template. An ex vivo rat model and an in vivo rabbit model of stromelysin-induced cartilage degradation were used to further optimize these analogs for oral activity and duration of action. The culmination of these modifications resulted in CGS 27023A, a potent, orally active stromelysin inhibitor that blocks the erosion of cartilage matrix.

  DOI：

  10.1021/jm960871c

文献信息

• C-PROTEINASE INHIBITORS FOR THE TREATMENT OF DISORDERS RELATED TO THE OVERPRODUCTION OF COLLAGEN
  申请人：FIBROGEN, INC.

  公开号：EP0845987A1

  公开（公告）日：1998-06-10
• EP0845987A4
  申请人：——

  公开号：EP0845987A4

  公开（公告）日：2000-05-24
• [EN] C-PROTEINASE INHIBITORS FOR THE TREATMENT OF DISORDERS RELATED TO THE OVERPRODUCTION OF COLLAGEN<br/>[FR] INHIBITEURS DE LA C-PROTEINASE DESTINES AU TRAITEMENT DES AFFECTIONS LIEES A LA SURPRODUCTION DE COLLAGENE
  申请人：FIBROGEN, INC.

  公开号：WO1997005865A1

  公开（公告）日：1997-02-20

  (EN) The present invention relates to the novel use of organic molecules capable of inhibiting C-proteinase activity in order to regulate, modulate and/or inhibit abnormal collagen formation.(FR) Utilisation nouvelle de molécules organiques capables d'inhiber l'activité de la C-protéinase afin de réguler, moduler et/ou prévenir une formation anormale de collagène.